A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : GLP-1RAs / GLP-1 receptor agonists

[Related PubMed/MEDLINE]
Total Number of Papers: 44
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   GLP-1RAs  (>> Co-occurring Abbreviation)
Long Form:   GLP-1 receptor agonists
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A glycosylated Fc-fused GLP-1 exhibits equivalent glucose lowering effect but lesser gastrointestinal side effect than Dulaglutide. ---
2020 Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass. BMD, BTMs, MC4R
2020 Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes. GLP-1, T2DM
2020 Drug discovery approaches targeting the incretin pathway. ---
2020 GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease-A Systematic Review. DPP-4, GIP, GIPRAs, GLP-1
2020 Incretin therapy for diabetes mellitus type 2. ---
2020 Magnitude of slowing gastric emptying by glucagon-like peptide-1 receptor agonists determines the amelioration of postprandial glucose excursion in Japanese patients with type2 diabetes. GE, GEC, GLP-1
2020 Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials. AP, CI, CVOTs, IBTs, OR
2020 Short-term GLP-1 receptor agonist exenatide ameliorates intramyocellular lipid deposition without weight loss in ob/ob mice. AMPK, DIO, T2D
10  2019 Cardiovascular outcome trials of glucose-lowering medications: an update. CV, CVD, CVOTs, DPP4, MACE, SGLT2
11  2019 Combination of GLP-1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: A retrospective cohort study. ENE
12  2019 Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study. BI, FPG, MVA, PSM, SBP, T2D
13  2019 GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials. CENTRAL, CI, OR, T2DM
14  2019 Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases. AD, DA, GLP-1, PD
15  2019 Long-term effects of GLP-1 receptor agonists in type 2 diabetic patients: A retrospective real-life study in 131 patients. BMI
16  2019 Patient preferences for treatment in type 2 diabetes: the Italian discrete-choice experiment analysis. ---
17  2019 The Discovery and Development of Liraglutide and Semaglutide. CV, GLP-1, GLP-1R, NASH, T2D
18  2019 [New glucose-lowering drugs for reducing cardiovascular risk in patients with type2 diabetes mellitus]. CV, DKD, SGLT-2i
19  2018 A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes. FPG, GLP-1, HTA, NMA, OADs, SBP, SR
20  2018 A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Anti-Diabetic Drugs. AEs, GLP-1, NMA, OADs, SBP, SLR, T2D
21  2018 A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin. GLP-1, NMA, T2D
22  2018 Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitor as an Add-on Drug to GLP-1 Receptor Agonists for Glycemic Control of a Patient with Prader-Willi Syndrome: A Case Report. PWS, SGLT2
23  2018 Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism. BMD, GIP, GLP-1
24  2018 GLP-1 receptor agonist liraglutide exerts central action to induce beta-cell proliferation through medulla to vagal pathway in mice. AP, i.c.v, NTS, s.c
25  2018 Neuroprotective Mechanisms of Glucagon-like Peptide-1-based Therapies in Ischaemic Stroke: A Systematic Review based on Pre-Clinical Studies. DPP-4is, GLP-1
26  2018 The Clinical Impact of GLP-1 Receptor Agonists in Type 2 Diabetes: Focus on the Long-Acting Analogs. ---
27  2017 Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials. NMA
28  2017 Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome. GLP-1, PCOS, T2DM
29  2016 An overview of new GLP-1 receptor agonists for type 2 diabetes. T2DM
30  2016 Baseline ALT levels as a marker of glycemic response to treatment with GLP-1 receptor agonists. BMI
31  2016 Glucagon like peptide-1 receptor agonists may ameliorate the metabolic adverse effect associated with antiretroviral therapy. ART, GLP-1, PLWHA
32  2016 Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future. ADA/EASD, GLP-1
33  2016 Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. DPP-4, GLP-1, T2D
34  2016 Investigational glucagon-like peptide-1 agonists for the treatment of obesity. T2DM
35  2015 GLP-1 Receptor Agonist Exenatide Increases Capillary Perfusion Independent of Nitric Oxide in Healthy Overweight Men. GLP-1
36  2015 GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women. BMC, GLP
37  2015 Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetes. ALP, BMSCs, Col1, PPARgamma
38  2014 Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying--preclinical evidence. GLP-1, PPG
39  2014 GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? DPP-4, GLP-1, T2D
40  2014 Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial. FPG, MODY, PG
41  2013 Incretin hormones and the satiation signal. GLP-1
42  2013 Incretin-based therapy in combination with basal insulin: a promising tactic for the treatment of type 2 diabetes. DPP-4is
43  2013 The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway. DPP-4, GLP-1
44  2012 Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice. ACF, DPP-4, GLP-1, GLP-2, MDF, T2DM